Article
Polymorphic NATs and cancer predisposition.
IARC scientific publications - 1 Jan 1999
Hirvonen A
Abstract excerpt
The acetylation polymorphism, discovered 40 years ago, holds a special place as one of the first described examples of a pharmacogenetic defect affecting xenobiotic biotransformation capacity in human populations. The genetically determined N-acetyltransferase activity is involved in activation/inactivation reactions of numerous xenobiotics. Therefore, it has been suggested that slow acetylator status may modify...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
